文章摘要

参考文献/References

［1］ Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction［J］. Vasc Health and Risk Manag, 2006, 2(2):153-156.

［2］Corsetti JP, Rainwater DL, Moss AJ, et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients［J］. Clin Chem, 2006, 52(7):1331-1338.

［3］李巧汶，邱健. 炎症标记物与冠心病关系的研究进展［J］. 心脏杂志, 2008, 20(3):359-362.

［4］朱毓,吴美华. 脂蛋白相关磷脂酶A2与动脉粥样硬化性疾病［J］. 心脏杂志, 2008, 20(1):101-103.

［5］ Brilakis ES, McConnell JP, Lennon RJ , et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angio-graphic coronary artery disease, and major adverse events at follow-up［J］ . Eur Heart J, 2005, 26(2):137-144.

［6］ Pión P, Kaski JC. Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?［J］. Rev Esp Cardiol, 2006, 59(3):247- 258.

［7］Sudhir K. Clinical review: Lipoprotein-asso-ciated phospholipase A2, a novel inflammatory biomarker and independent risk predictorfor cardiovascular disease［J］ . J Clin Endocrinol Metab, 2005, 90(5):3100-3105.

［8］ Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans［J］. Arterioscler Thromb Vasc Biol, 2006, 26(1):106-111.

［9］ Iribarren C, Gross MD, Darbinian JA, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study［J］. Arterioscler Thromb Vasc Biol, 2005, 25(1):216-221.

［10］Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study［J］. Circulation, 2005, 111(5):570-575.

［11］Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis［J］. Arterioscler Thromb Vasc Biol, 2006, 26(11):2523-2529.

［12］Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development［J］. Nat Med, 2008, 14(10):1015-1016.

［13］Anderson JL. Lipoprotein-associated phosp holipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention［J］. Am J Cardiol, 2008, 101(12A):23F-33F.

[14]Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress［J］. Arterioscler Thromb Vasc Biol, 2006, 26(7):1586-1593.

[15]ODonoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial［J］. Circulation, 2006, 113(14):1745-1752.

［16］Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study［J］. Circulation, 2005, 111(8):980-987.

我们的网站为什么显示成这样？

LP-PLA2与冠状动脉粥样硬化性心脏病的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics